Keung et al. (2016) showed that RRg3 exerted its anti-angiogenic effects via an increased expression of hsa-miR-520h, which targeted ephrin type-B receptor 2 (EphB2) and EphB4 as a mediator of cancer migration and angiogenesis [32]. The gene discussed is EPHB4; the disease is cancer.